Use of topical immunomodulators in organ transplant recipients.
Solid organ transplant recipients are a growing population at increased risk for the development of cutaneous premalignant and malignant lesions, resulting in significant morbidity and mortality. Topical immunomodulators, in particular imiquimod, have shown efficacy in the management of multiple malignant, precancerous, and viral conditions. The ability to locally induce an immune response, presumably against tumor and viral antigens, and induce apoptosis makes topical immunomodulators a promising therapeutic option in organ transplant recipients. Although limited, data have begun to accumulate on the use of imiquimod in transplant patients for the management of superficial, nodular, and infiltrative basal cell carcinomas; in situ and invasive squamous cell carcinomas; condyloma acuminata; and common warts. As more experience is gathered, the role of imiquimod and other topical immunomodulators in the care of OTRs will be clarified. The authors reviewed the existing data on the use of topical imiquimod in OTRs with mention of its presumed mechanisms of action and other immunomodulators with potential efficacy against cancerous and precancerous lesions.
Kovach
Bradley T
BT
Division of Dermatology, Vanderbilt University, Nashville, TN 37232-5227, USA.
Stasko
Thomas
T
D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D000077271:Imiquimod; D007155:Immunologic Factors / Q000008:administration & dosage / Q000276:immunology*; D016377:Organ Transplantation; D012878:Skin Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D007155:Immunologic Factors; D000077271:Imiquimod